<?xml version="1.0" encoding="UTF-8"?>
<p>Actemra/Tocilizumab; Avigan/Favipiravir; Azithromycin; Baricitinib/Olumiant; Bevacizumab/Avastin; Calquence/Acalabrutinib; Chloroquine; Colcrys/Colchicine; Convalescent Plasma; EIDD-2801; Fingolimod/Gilenya; Galidesivir; Hydroxychloroquine; Ilaris/Canakinumab; Ivermectin; Jakafi/Ruxolitinib; Kaletra/Lopinavir/Ritonavir; Kevzara/Sarilumab; Kineret/Anakinra; Leronlimab; Mavrilimumab; Methylprednisolone; Olumiant/Baricitinib; Otezla/Apremilast; Remdesivir; Tamiflu/Oseltamivir; Umifenovir/Arbidol; Xeljanz/Tofacitinib (
 <ext-link ext-link-type="uri" xlink:href="https://milkeninstitute.org/covid-19-tracker" xmlns:xlink="http://www.w3.org/1999/xlink">https://milkeninstitute.org/covid-19-tracker</ext-link>; 
 <ext-link ext-link-type="uri" xlink:href="https://www.drugs.com/condition/covid-19.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.drugs.com/condition/covid-19.html</ext-link>; 
 <ext-link ext-link-type="uri" xlink:href="https://www.goodrx.com/blog/coronavirus-treatments-on-the-way/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.goodrx.com/blog/coronavirus-treatments-on-the-way/</ext-link>). The treatment trials have met with mixed results, and, in any case, do little, if anything, to strengthen the weakened immune systems of the most vulnerable. After such tactical treatments for one viral infection, people with weakened immune systems will again be vulnerable to serious infectious consequences from exposure to the next harmful virus they encounter, unless they take active measures to strengthen their immune systems. Local treatments (aerosol, inhalers, nebulizers) may offer some benefit of achieving ther-apeutic concentrations in affected tissues with lower adverse effects (
 <xref rid="b16-ijmm-46-02-0463" ref-type="bibr">16</xref>).
</p>
